CD19-targeting immunotherapies, such as the bispecific T-cell engager (BiTE) blinatumomab, are effective at treating relapsed and refractory pediatric B-cell acute lymphoblastic leukemia (B-ALL) (1, 2). This evidence concerns the gene CD19 and B-cell acute lymphoblastic leukemia.